CHOP + Zevalin and Rituxan better than CHOP + Rituxan Alone

Results from a phase II clinical trial reported that CHOP-R followed by Zevalin (90Y ibritumomab tiuxetan) and Rituxan (rituximab, MabThera outside the US) provides high complete response rates and encouraging progression-free survival as initial treatment of follicular non-Hodgkin’s lymphoma (NHL). These results were presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO).

More info in a press release.

LymphomaInfo Social